Leilana Ly

887 total citations
8 papers, 61 citations indexed

About

Leilana Ly is a scholar working on Oncology, Cancer Research and Surgery. According to data from OpenAlex, Leilana Ly has authored 8 papers receiving a total of 61 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Cancer Research and 2 papers in Surgery. Recurrent topics in Leilana Ly's work include Pancreatic and Hepatic Oncology Research (4 papers), Cancer Genomics and Diagnostics (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Leilana Ly is often cited by papers focused on Pancreatic and Hepatic Oncology Research (4 papers), Cancer Genomics and Diagnostics (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Leilana Ly collaborates with scholars based in United States. Leilana Ly's co-authors include Colin D. Weekes, Lawrence S. Blaszkowsky, David P. Ryan, Jennifer Y. Wo, Jill N. Allen, Jeffrey W. Clark, David T. Ting, Beow Y. Yeap, Theodore S. Hong and Aparna R. Parikh and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

Leilana Ly

7 papers receiving 60 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Leilana Ly United States	4	54	14	12	12	9	8	61
Ana-Maria Mușină Romania	5	57 1.1×	17 1.2×	13 1.1×	16 1.3×	6 0.7×	11	79
Dafina Nikolova North Macedonia	4	32 0.6×	11 0.8×	9 0.8×	16 1.3×	14 1.6×	16	51
Simona Ruisi Italy	2	36 0.7×	10 0.7×	8 0.7×	20 1.7×	10 1.1×	2	71
Coriolan Lebreton France	5	44 0.8×	6 0.4×	11 0.9×	8 0.7×	12 1.3×	28	76
Setareh Samimi Canada	4	72 1.3×	30 2.1×	17 1.4×	8 0.7×	10 1.1×	8	77
Antonella Cammarota Italy	6	36 0.7×	22 1.6×	9 0.8×	6 0.5×	23 2.6×	18	77
Jiyu Wen China	3	36 0.7×	5 0.4×	11 0.9×	7 0.6×	14 1.6×	6	48
Yumi Kosaka Japan	5	52 1.0×	20 1.4×	5 0.4×	6 0.5×	19 2.1×	5	83
Sanya Arshad United States	5	29 0.5×	10 0.7×	28 2.3×	10 0.8×	6 0.7×	7	64
Andressa Dias Costa United States	4	29 0.5×	4 0.3×	8 0.7×	11 0.9×	6 0.7×	14	50

Countries citing papers authored by Leilana Ly

Since Specialization

Citations

This map shows the geographic impact of Leilana Ly's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leilana Ly with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leilana Ly more than expected).

Fields of papers citing papers by Leilana Ly

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leilana Ly. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leilana Ly. The network helps show where Leilana Ly may publish in the future.

Co-authorship network of co-authors of Leilana Ly

This figure shows the co-authorship network connecting the top 25 collaborators of Leilana Ly. A scholar is included among the top collaborators of Leilana Ly based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leilana Ly. Leilana Ly is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Russo, Andrea, Nicolas Depauw, Nora Horick, et al.. (2025). Long-Term Results of a Phase 2 Study of Adjuvant Proton Radiation Therapy for Node-Positive Cancer of the Uterus and Cervix. International Journal of Radiation Oncology*Biology*Physics. 122(5). 1301–1309. 1 indexed citations

Roberts, Hannah, Beow Y. Yeap, Julie L. Koenig, et al.. (2024). SBRT with ipilimumab and nivolumab to metastatic MSS colorectal and pancreatic cancer: A pooled analysis of four prospective phase II trials.. Journal of Clinical Oncology. 42(3_suppl). 752–752.

Hong, Theodore S., Beow Y. Yeap, Nora Horick, et al.. (2023). A multicenter, randomized phase II study of total neoadjuvant therapy (TNT) with FOLFIRINOX (FFX) and SBRT, with or without losartan (L) and nivolumab (N) in borderline resectable (BR) and locally advanced (LA) pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. 41(4_suppl). 719–719. 10 indexed citations

Parikh, Aparna R., Colin D. Weekes, Lawrence S. Blaszkowsky, et al.. (2022). A phase II study of niraparib and dostarlimab with radiation in patients with metastatic pancreatic cancer.. Journal of Clinical Oncology. 40(4_suppl). 564–564. 4 indexed citations

Parikh, Aparna R., Jeffrey W. Clark, Jennifer Y. Wo, et al.. (2019). Proof of concept of the abscopal effect in MSS GI cancers: A phase 2 study of ipilimumab and nivolumab with radiation in metastatic pancreatic and colorectal adenocarcinoma. Annals of Oncology. 30. iv128–iv128. 2 indexed citations

Parikh, Aparna R., Jennifer Y. Wo, David P. Ryan, et al.. (2019). A phase II study of ipilimumab and nivolumab with radiation in metastatic pancreatic adenocarcinoma.. Journal of Clinical Oncology. 37(4_suppl). 391–391. 10 indexed citations

Murphy, Janet E., Leilana Ly, Jennifer Y. Wo, et al.. (2019). Dose intensity of neoadjuvant FOLFIRINOX (FFX) in borderline and locally advanced pancreatic cancer (LAPC): A comparison to the adjuvant benchmark.. Journal of Clinical Oncology. 37(4_suppl). 392–392. 3 indexed citations

Parikh, Aparna R., Jeffrey W. Clark, Jennifer Y. Wo, et al.. (2019). A phase II study of ipilimumab and nivolumab with radiation in microsatellite stable (MSS) metastatic colorectal adenocarcinoma (mCRC).. Journal of Clinical Oncology. 37(15_suppl). 3514–3514. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact